GE HealthCare said fourth-quarter revenue of Q4 2024 rose 2% year over year on both a reported and Organic basis to $5.3 billion, net income margin was 13.5% versus 7.7% a year earlier, and Adjusted EBIT margin was 18.7% versus 16.1%. Diluted EPS was $1.57 versus $0.88.

1. 01

   GE HealthCare said fourth-quarter revenue of Q4 2024 rose 2% year over year on both a reported and Organic basis to $5.3 billion, net income margin was 13.5% versus 7.7% a year earlier, and Adjusted EBIT margin was 18.7% versus 16.1%. Diluted EPS was $1.57 versus $0.88.

2. 02

   The company said cash flow from operating activities for 2024 was $2.0 billion, down $146 million year over year, and free cash flow was $1.6 billion, down $161 million. Free cash flow conversion for the year was 75%.

3. 03

   The company said Pharmaceutical Diagnostics segment revenue for Q4 2024 was $646 million, up 9% year over year, and its Segment EBIT Margin was 32.9%. Advanced Visualization Solutions revenue was $1,440 million, up 4%.

4. 04

   The company gave its outlook for 2025, calling for Organic revenue growth of 2% to 3%, Adjusted EBIT margin of 16.7% to 16.8%, Adjusted EPS of $4.61 to $4.75, and free cash flow of at least $1.75 billion. It said the outlook includes the estimated impact of recently implemented U.S. tariffs on products from China.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.